TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00424944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 (malaria vaccine)
Description: 100 micrograms of GMZ2 in each vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GMZ2 (malaria vaccine)
Description: 100 micrograms of GMZ2 in each vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 malaria vaccine
Description: 100 micrograms of GMZ2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Verorab vaccine
Description: Anti-rabies vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab vaccine
Description: Anti-rabies vaccine
Study: NCT02434822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration
Study: NCT03546556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine (FLT)
Description: A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Study: NCT02594254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00608075

Intervention type: DRUG
Group type: OTHER
Intervention: lithium
Description: 600 mg - 1800 mg per day

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: 600 - 1800 mg
Study: NCT02863874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VicrylPlus®
Description: Suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl®
Description: Suture
Study: NCT03083457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
Study: NCT03554928

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: Participants will receive a 60 minute magnetic resonance imaging assessment
Study: NCT03083457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
Study: NCT03083457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: Total intravenous anesthesia with a standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: Total intravenous anesthesia with a standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: Total intravenous anesthesia with a standard protocol
Study: NCT02936817

Intervention type: DEVICE
Group type: OTHER
Intervention: Aerobika® Device
Description: For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).

Intervention type: RADIATION
Group type: OTHER
Intervention: HRCT scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
Study: NCT03499093

Intervention type: OTHER
Intervention: OES
Description: The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test.
Study: NCT02102113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose THC
Description: Subjects will receive 0.018 mg/kg over 20 minutes.
Study: NCT03499093

Intervention type: OTHER
Intervention: OES
Description: The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test.

Intervention type: OTHER
Intervention: OES
Description: The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test.
Study: NCT02102113

Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose THC
Description: Subjects will receive 0.018 mg/kg over 20 minutes.
Study: NCT04538976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil in standard dosage
Study: NCT01833559

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary control

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary control

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary control

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
Study: NCT03117855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Undergo yttrium Y-90 radioembolization
Study: NCT01440855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIS (Cancer Information Service) Information Sheet
Description: CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
Study: NCT03083457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
Study: NCT01440855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facing Forward booklet
Description: NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
Study: NCT01302353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane
Study: NCT03083457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
Study: NCT01302353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane
Study: NCT03083457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
Study: NCT01302353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane
Study: NCT03083457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scheduled recruiting maneuvers
Description: Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
Study: NCT03083457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scheduled recruiting maneuvers
Description: Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scheduled recruiting maneuvers
Description: Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
Study: NCT03546270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swimming
Description: This group completed 20-weeks of swimming
Study: NCT04231799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing
Description: Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
Study: NCT05306613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking sitting
Description: After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
Study: NCT01302353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane
Study: NCT03161652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DME lactose pill
Description: Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DME levosulpiride
Description: Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study: NCT00251680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and lipid-lowering therapy
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid-lowering therapy
Description: Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Study: NCT03161652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DR lactose pill
Description: Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Study: NCT04518800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jin Youli(PEG-rhG-CSF)
Description: Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
Study: NCT03161652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR levosulpiride
Description: Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study: NCT01701180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU; 3 puffs per nostril, each with 4 IU OXT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01383759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Description: The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments.
Study: NCT02848859

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! to Sleep
Description: This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Sleep Education
Description: Providing patients information on healthy sleep and habits to promote healthy sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Sleep Education
Description: Providing patients information on healthy sleep and habits to promote healthy sleep.
Study: NCT02469558

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove 851 and 110
Description: prebiotic and probiotic mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white powder without pro/probiotic
Study: NCT02201732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.